Publications
2013
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.
Rumi E,
Milosevic JD,
Casetti I,
Dambruoso I,
Pietra D,
Boveri E,
Boni M,
Bernasconi P,
Passamonti F,
Kralovics R,
Cazzola M.
J Clin Oncol. 2013 Jun 10; 31(17):e269-71.
2013
Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
Rommer A,
Steinleitner K,
Hackl H,
Schneckenleithner C,
Engelmann M,
Scheideler M,
Vlatkovic I,
Kralovics R,
Cerny-Reiterer,
Valent P,
Sill H,
Wieser R.
BMC Cancer. 2013; 13: 364.
2013
Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Gisslinger H,
Schalling M,
Gisslinger B,
Skrabs C,
Müllauer L,
Kralovics R.
Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23637. [Epub ahead of print]
2013
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H,
Gotic M,
Holowiecki J,
Penka M,
Thiele J,
Kvasnicka H-M,
Kralovics R,
Petrides PE,
Gastl G,
Gisslinger B,
Muellauer L,
Schlögl E,
Indrak K,
Pytlik R,
Briere K,
Kiladjian JJ,
Beykirch M,
Gaede B,
Griesshammer M,
Herbrik-Zipp M,
Hurtz HJ,
Jacobs G,
Jäcki SH,
Keilholz U,
MezgerJ,
Schlag P,
Schriever F,
Masszi T,
Sacchi S,
Griniptì R ,Tavoriene I,
Dmoszynska A,
Hellman A,
Jedrzejczak WW,
Robak T,
SkotnickiA,
Goh YT,
Cernelc P.
Blood. 2013 March 7; 121(10): 1720–1728.
2013
Molecular basis and clonal evolution of myeloproliferative neoplasms.
Cleary C,
Kralovics R.
Clin Chem Lab Med. 2013 Oct 1; 51(10):1889-96.
